Latest Articles
GIST, SNUH identify beneficial bacterium linked to lower endometrial cancer recurrence - koreabiomed.com
GIST, SNUH identify beneficial bacterium linked to lower endometrial cancer recurrence koreabiomed.com
Published: May 20, 2026, 7:57 a.m.
Merck's Sac-TMT meets both endpoints in phase 3 endometrial cancer trial - MSN
Merck's Sac-TMT meets both endpoints in phase 3 endometrial cancer trial MSN
Published: May 20, 2026, 6:16 a.m.
How Sacituzumab Trial Success In Endometrial Cancer At Merck (MRK) Has Changed Its Investment Story - simplywall.st
How Sacituzumab Trial Success In Endometrial Cancer At Merck (MRK) Has Changed Its Investment Story simplywall.st
Published: May 20, 2026, 5:46 a.m.
It has been revealed why the recurrence rate of endometrial cancer, one of the representative female.. - 매일경제
It has been revealed why the recurrence rate of endometrial cancer, one of the representative female.. 매일경제
Published: May 20, 2026, 4:30 a.m.
‘Actress Amy Schumer, 44, Recent Colonoscopy Helps Reduce Cancer Risks By Wiping Out Precancerous Polyps Proactively, But She Says Her Procedure Left Her Recovering Longer Than Expected - SurvivorNet
‘Actress Amy Schumer, 44, Recent Colonoscopy Helps Reduce Cancer Risks By Wiping Out Precancerous Polyps Proactively, But She Says Her Procedure Left Her Recovering Longer Than Expected SurvivorNet
Published: May 19, 2026, 9:40 p.m.
Pfizer Takes Aim at Merck in New Phase 3 Endometrial Cancer Trial - TipRanks
Pfizer Takes Aim at Merck in New Phase 3 Endometrial Cancer Trial TipRanks
Published: May 19, 2026, 4:44 p.m.
Merck's ADC Candidate Meets Goals in Endometrial Cancer Study - Yahoo Finance
Merck's ADC Candidate Meets Goals in Endometrial Cancer Study Yahoo Finance
Published: May 19, 2026, 3:47 p.m.
GLP-1s May Help Reduce Endometrial Cancer Risk in Patients With Obesity and Metabolic Disease - Pharmacy Times
GLP-1s May Help Reduce Endometrial Cancer Risk in Patients With Obesity and Metabolic Disease Pharmacy Times
Published: May 19, 2026, 3:15 p.m.
KPTI: SENTRY and ECO42 trials highlight selinexor's promise in myelofibrosis and endometrial cancer - TradingView
KPTI: SENTRY and ECO42 trials highlight selinexor's promise in myelofibrosis and endometrial cancer TradingView
Published: May 19, 2026, 2 p.m.
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer - BioSpace
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer BioSpace
Published: May 19, 2026, 11:19 a.m.
Link copied to clipboard!